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GUEST EDITORIAL
Curing gastric cancer - hone the scalpel with magic?
A Webb and D Cunningham
The Cancer Research Campaign Section ofMedicine and The GI Unit, The Royal Marsden Hospital, and The Institute ofCancer
Research, Sutton, Surrey SM2 5PT, UK.
Tis true; there's magic in the web of it
(Othello, Act 3, scene 4, line 70)
Gastric cancer is a common tumour that represents a
number of challenges for both oncologists and surgeons. In
Europe and America the incidence appears to be declining
overall, with an apparent increase in the proportion of
proximal lesions and a decrease in the proportion of distal
and antral cancers. Only approximately 20% of patients
present with surgically curative disease and the operative
mortality rates still remain significant. Overall 5 year
survival is approximately 5%, reflecting the high proportion
of advanced disease. Survival for curative resections is
dependent upon stage (Fielding et al., 1984). In a large UK
series 5 year survival for stage I, II and III disease was 72%,
32% and 10% respectively (Allum et al., 1989). In Japan
extensive lymphadenectomy in addition to excision of the
primary lesion is routinely used, however, a survival
advantage for this approach is unproven. Currently there
are two randomised trials comparing extensive with limited
lymph node dissection: one of these is being undertaken by
the Medical Research Council (MRC), the other by a group
in Holland. Neither of these have reported on their survival
results, but the Dutch study of 996 patients resulted in a
higher operative mortality rate and complication rate in
patients undergoing the more extensive dissection (Bonen-
kamp et al., 1995).
There have been a number of randomised trials
investigating adjuvant chemotherapy, all of which were
small in size and have used less than optimal chemother-
apy. A meta-analysis in 1993 of 11 trials and 2096 patients
demonstrated no significant benefit in terms of additional
survival in patients having adjuvant therapy (Hermans et al.,
1993). However, this report was later criticised for failing to
include two eligible trials found in a more exhaustive search
of the literature and when these data were included the
common odds ratio of 0.82 (95% confidence interval 0.68-
0.98) was obtained in favour of the adjuvant chemotherapy
group (Hermans and Bonenkamp, 1993). The meta-analysis
did not include two randomised Japanese trials performed
before 1980 that used single agent intravenous mitomycin C
(Imanaga and Nakazato, 1977; Nakajima et al., 1978), one of
which demonstrated a significant survival advantage in
favour of the treatment arm and was the basis for the
routine treatment of Japanese patients with adjuvant
chemotherapy. More recently, and since the meta-analysis,
the adjuvant use of intraperitoneal carbon absorbed
mitomycin C in T3 and T4 tumours has shown a highly
significant improvement in 3 year survival (Hagiwara et al.,
1992) and enlargement of a Spanish trial included in the
meta-analysis has shown that the survival advantage is
maintained in the treatment arm using single agent
intravenous mitomycin C (Grau et al., 1993). In contrast
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the British Stomach Cancer Group reported no 5 year
survival difference for adjuvant chemotherapy (FAM; 5FU,
doxorubicin, mitomycin C) or adjuvant radiotherapy in a
trial of 436 patients (Hallissey et al., 1994).
The study by Neri et al. in this issue is a prospective
randomised trial of 5FU, leucovorin and epidoxorubicin vs
surgery alone in node-positive gastric cancers (Neri et al.,
1995). It is a relatively small study with 112 patients
randomised and the major impact of chemotherapy was to
delay time of recurrence, although it is still possible that a
small but clinically relevant effect may be seen in survival
with longer follow-up. This is the first adjuvant study to use a
highly promising regimen with tolerable toxicity. The phase
II results in advanced disease demonstrated a response rate of
49% with a 6% complete response in 35 patients (Neri et al.,
1993).
In theory the best regimens for adjuvant chemotherapy are
those that result in a high response rate and complete
response rate when tested in patients with advanced disease.
On this basis FAMTX (5FU, doxorubicin, methotrexate)
would be the best regimen according to randomised studies.
FAMTX demonstrated a survival and response rate
advantage when compared with FAM (5FU, doxorubicin
C, mitomycin C; Wils et al., 1991), and when compared with
the highly promising regimen of EAP (etoposide, doxorubicin
and cisplatin) there was no significant difference in response
or survival, but the EAP regimen was unacceptably toxic
(Kelsen et al., 1992). More recently preliminary analysis of a
three-way randomised trial comparing FAMTX with ELF
(etoposide, leucovorin, 5FU) or cisplatin/5FU demonstrated
no significant response or survival differences between the
three regimens (Wilke et al., 1995). The regimen ECF
(epirubicin, cisplatin, protracted venous infusion 5FU),
developed at the Royal Marsden Hospital, demonstrated
promising phase II results with overall objective response
rates of 71% including 12% complete responses. The
response rate in locally advanced disease was 80% with
23% achieving a complete response, and four patients having
a pathological complete response in resected- specimens
(Findlay et al., 1994). The preliminary unpublished results
of the multicentre trial comparing ECF with FAMTX in 274
patients have demonstrated a significant survival advantage
for the ECF arm (P = 0.0009) with further analysis of
response rate, toxicity and quality of life awaited. The data
from this randomised trial indicate that ECF is the most
effective chemotherapy treatment for gastric cancer and these
results underpin the importance of the recently launched
MRC/British Stomach Cancer Group (BSCG) study. The
MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC)
trial is a randomised trial investigating perioperative ECF in
patients with operable disease vs surgery alone. This design
has some potential advantages over a purely adjuvant trial in
that micrometastases are treated relatively early in the course
of the disease, tumours may be downstaged, enabling less
extensive surgery and the patients, nutritional status should
be improved before surgery. In addition, the incidence of
progression on ECF chemotherapy in patients with locally
advanced disease is rare (7%) according to our database, andCuring gastric cancer
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therefore reassures surgical colleagues that delay will not
compromise outcome. Furthermore in the MRC STOI trial,
737 patients were registered with potentially surgically
resectable disease on preoperative assessment but only 400
patients could have curative surgery, which highlights the
need for preoperative chemotherapy to downstage tumours
and thereby increase the curative resection rate.
Adjuvant chemotherapy following surgery in gastric cancer
should not yet be regarded as a standard treatment.
However, the results of Neri et al. are encouraging and
reinforce the potential role for more effective regimens such
as ECF. Moreover, if the downstaging seen with ECF in
patients with locally advanced gastric cancer is translated into
patients with operable tumour, then the use of perioperative
chemotherapy may increase the role of radical surgery.
Rolling back the frontiers of gastric cancer was never going
to be easy, but if we can attract surgeons and oncologists
with vision to participate in the MAGIC trial, who knows
what the future may bring.
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